Andros Pharmaceuticals Co (ROCO:6917) Beneish M-Score: 20.46 (As of Jul. 17, 2026) — 537% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6917 Andros Pharmaceuticals Co Ltd ROCO:6917
41 GF Score
Price NT$34.50
GF Value NT$165.02
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Andros Pharmaceuticals Co Beneish M-Score?

Andros Pharmaceuticals Co ROCO:6917 -3.09% 41 Beneish M-Score is 20.46 as of Jul. 17, 2026, which is 537% above its 10-year median of 3.21. GuruFocus rates ROCO:6917 with a GF Score™ of 41/100 and a GF Value™ of NT$165.02 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 824 Biotechnology companies, Andros Pharmaceuticals Co ranks worse than 95.75% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 20.46 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Andros Pharmaceuticals Co's Beneish M-Score or its related term are showing as below:

ROCO:6917' s Beneish M-Score Range Over the Past 10 Years
Min: -3.94   Med: 3.21   Max: 20.46
Current: 20.46

During the past 7 years, the highest Beneish M-Score of Andros Pharmaceuticals Co was 20.46. The lowest was -3.94. And the median was 3.21.


Andros Pharmaceuticals Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Andros Pharmaceuticals Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Andros Pharmaceuticals Co Beneish M-Score Chart

Andros Pharmaceuticals Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial -0.27 6.00 -3.94 3.21 20.46

Andros Pharmaceuticals Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.94 0.00 3.21 0.00 20.46

ROCO:6917 vs VRTX, REGN, ALNY: Beneish M-Score Comparison

For the Biotechnology subindustry, Andros Pharmaceuticals Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Andros Pharmaceuticals Co Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Andros Pharmaceuticals Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Andros Pharmaceuticals Co's Beneish M-Score falls into.


ROCO:6917
41GF Score
Andros Pharmaceuticals Co Ltd ROCO:6917
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Andros Pharmaceuticals Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Andros Pharmaceuticals Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.0803+0.528 * 0.1518+0.404 * 2.4415+0.892 * 27.33+0.115 * 0.7647
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.0395+4.679 * -0.014904-0.327 * 0.7156
=20.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$1.08 Mil.
Revenue was NT$5.55 Mil.
Gross Profit was NT$1.80 Mil.
Total Current Assets was NT$382.98 Mil.
Total Assets was NT$558.97 Mil.
Property, Plant and Equipment(Net PPE) was NT$21.31 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$6.76 Mil.
Selling, General, & Admin. Expense(SGA) was NT$19.26 Mil.
Total Current Liabilities was NT$27.42 Mil.
Long-Term Debt & Capital Lease Obligation was NT$11.77 Mil.
Net Income was NT$-53.78 Mil.
Gross Profit was NT$0.00 Mil.
Cash Flow from Operations was NT$-45.45 Mil.
Total Receivables was NT$0.49 Mil.
Revenue was NT$0.20 Mil.
Gross Profit was NT$0.01 Mil.
Total Current Assets was NT$364.37 Mil.
Total Assets was NT$441.48 Mil.
Property, Plant and Equipment(Net PPE) was NT$27.08 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$6.12 Mil.
Selling, General, & Admin. Expense(SGA) was NT$17.86 Mil.
Total Current Liabilities was NT$26.39 Mil.
Long-Term Debt & Capital Lease Obligation was NT$16.86 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1.084 / 5.548) / (0.494 / 0.203)
=0.195386 / 2.433498
=0.0803

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(0.01 / 0.203) / (1.8 / 5.548)
=0.049261 / 0.324441
=0.1518

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (382.981 + 21.308) / 558.972) / (1 - (364.365 + 27.076) / 441.48)
=0.276728 / 0.113344
=2.4415

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=5.548 / 0.203
=27.33

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(6.116 / (6.116 + 27.076)) / (6.764 / (6.764 + 21.308))
=0.184261 / 0.240952
=0.7647

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(19.262 / 5.548) / (17.862 / 0.203)
=3.471882 / 87.990148
=0.0395

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((11.766 + 27.418) / 558.972) / ((16.857 + 26.393) / 441.48)
=0.0701 / 0.097966
=0.7156

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-53.776 - 0 - -45.445) / 558.972
=-0.014904

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Andros Pharmaceuticals Co has a M-score of 20.46 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of 20.46 mean?
Andros Pharmaceuticals Co (ROCO:6917) has a Beneish M-Score of 20.46 as of Jul. 17, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Andros Pharmaceuticals Co and its competitors. This is 537% above median its historical median of 3.21. According to the industry distribution chart, Andros Pharmaceuticals Co ranks #789 out of 824 companies in the Biotechnology industry, placing it in the top 95.8%.
Is Andros Pharmaceuticals Co's Beneish M-Score too high?
Andros Pharmaceuticals Co's current Beneish M-Score of 20.46 is 537% above median its 10-year median of 3.21. Based on the distribution chart, Andros Pharmaceuticals Co ranks #789 out of 824 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Andros Pharmaceuticals Co has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Andros Pharmaceuticals Co's Beneish M-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Andros Pharmaceuticals Co ranks #789 out of 824 companies for Beneish M-Score. This places Andros Pharmaceuticals Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Andros Pharmaceuticals Co and its competitors. Andros Pharmaceuticals Co's current Beneish M-Score is 20.46, which is 537% above median its own 10-year median of 3.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Andros Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Andros Pharmaceuticals Co (ROCO:6917) is currently considered Possible Value Trap. The stock's GF Value™ is NT$165.02, compared to a current price of NT$34.50 — trading 79.1% below its estimated fair value. The current Beneish M-Score is 20.46, which is 537% above median its 10-year median of 3.21. Andros Pharmaceuticals Co's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Andros Pharmaceuticals Co (ROCO:6917), the current Beneish M-Score is 20.46 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Andros Pharmaceuticals Co (ROCO:6917) Overvalued in 2026?

Based on GuruFocus' analysis, Andros Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$34.50 is trading 79.1% below its estimated GF Value™ of NT$165.02. GuruFocus considers Andros Pharmaceuticals Co to be Possible Value Trap.

Key valuation signals for ROCO:6917:

  • Beneish M-Score: 20.46 (537% above median its 10-year median of 3.21)
  • GF Value™: NT$165.02 vs. price of NT$34.50 (79.1% below fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6917 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Andros Pharmaceuticals Co Business Description

Address No. 22, Sec. 2, Shengyi Road, 6th Floor, Building D, Biotech Building, Hsinchu Biomedical Science Park, Hsinchu County, Zhubei City, TWN, 30261
Andros Pharmaceuticals Co Ltd is a biopharmaceutical company engaged in developing novel drug delivery platform technologies. The firm focuses on the development of topical new dosage forms and non-viral gene delivery systems, with the current pipeline indicated for pain management, DNA repair, and gene therapy. Its product line comprises New Dosage Forms (Topical), Super Generics (Topical), High-End Cosmetic Ingredients (Topical), and Gene Delivery Systems (Injectable).
41GF Score

Get the complete analysis for ROCO:6917

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$34.50
Price
NT$165.02
GF Value